Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SHPG Shire (SHPG) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis Get Shire alerts: Email Address About Shire Stock (NASDAQ:SHPG) 30 days 90 days 365 days Advanced Chart Ad Porter & CompanyWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.Click here to learn how you can benefit from its widespread distribution. Get Shire alerts:Sign Up Key Stats Today's Range$179.20▼$179.2050-Day Range$179.20▼$179.2052-Week Range$123.73▼$182.47VolumeN/AAverage Volume2.21 million shsMarket Capitalization$54.71 billionP/E Ratio11.83Dividend Yield0.19%Price TargetN/AConsensus RatingN/A Company OverviewShire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.Read More… War on Elon Escalates… (Ad)Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.Click here to learn how you can benefit from its widespread distribution. Receive SHPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shire and its competitors with MarketBeat's FREE daily newsletter. Email Address SHPG Stock News HeadlinesSHPG Historical DataOctober 15, 2023 | investing.comShire Stock Hits New 52-Week High (SHPG)March 30, 2023 | thestreet.comJeff Bezos Just Humiliated Elon MuskThe Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.September 18, 2024 | InvestorPlace (Ad)Ethiopia's Tigray conflict: Nasa shows how a war zone faded from space - BBCOctober 19, 2022 | bbc.comEthiopia civil war: Hyenas scavenge on corpses as Tigray forces retreat - BBCOctober 18, 2022 | bbc.comEthiopia civil war: Federal army seizes strategic city of Shire - Yahoo NewsOctober 18, 2022 | news.yahoo.comEthiopian war in Tigray intensifies as government soldiers capture strategic Shire - The Washington PostOctober 17, 2022 | washingtonpost.comMum saves toddler with CPR in Sydney's Hills Shire: Triple-0 call revealed: Police Defibrillators - Daily MailSeptember 25, 2022 | dailymail.co.ukSee More Headlines SHPG Stock Analysis - Frequently Asked Questions How were Shire's earnings last quarter? Shire plc (NASDAQ:SHPG) announced its quarterly earnings results on Thursday, April, 26th. The biopharmaceutical company reported $3.86 EPS for the quarter, beating analysts' consensus estimates of $3.58 by $0.28. The business's revenue for the quarter was up 5.4% compared to the same quarter last year. What other stocks do shareholders of Shire own? Based on aggregate information from My MarketBeat watchlists, some other companies that Shire investors own include Gilead Sciences (GILD), Intel (INTC), Merck & Co., Inc. (MRK), Cisco Systems (CSCO), Walt Disney (DIS) and Johnson & Johnson (JNJ). Company Calendar Last Earnings4/26/2018Today9/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:SHPG CUSIPN/A CIK936402 Webwww.shire.com Phone353-1609-6000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)$15.15 Trailing P/E Ratio11.83 Forward P/E Ratio11.88 P/E Growth1.54Net Income$4.27 billion Net Margins30.63% Pretax MarginN/A Return on Equity12.70% Return on Assets7.06% Debt Debt-to-Equity Ratio0.36 Current Ratio0.92 Quick Ratio0.51 Sales & Book Value Annual Sales$15.16 billion Price / Sales3.61 Cash Flow$22.71 per share Price / Cash Flow7.89 Book Value$119.43 per share Price / Book1.50Miscellaneous Outstanding Shares305,280,000Free FloatN/AMarket Cap$54.71 billion OptionableOptionable Beta0.87 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:SHPG) was last updated on 9/18/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredCrypto ‘Banana Zone’ Incoming…What if I told you that bananas could make you a millionaire? No, this isn't a joke – I'm talking about the...Crypto 101 Media | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored625,000% GainThe recent crypto correction has shaken many investors, causing panic and uncertainty. But while others are fr...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shire plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Shire With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.